Drug intelligence / Profile preview

Protivity

Development stage: Unknown
Lead developer: Zoetis
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

Protivity is a modified-live bacterial vaccine developed by Zoetis for the protection of healthy beef and dairy calves against respiratory disease caused by *Mycoplasma bovis*. It is the first modified-live vaccine specifically developed for this pathogen, which is a significant contributor to the Bovine Respiratory Disease (BRD) complex. The vaccine contains an avirulent live culture of *M. bovis* and is administered subcutaneously in two doses, 21 days apart. It is approved for use in calves as young as one week of age. Clinical efficacy studies have shown that Protivity reduces lung lesions by 43.6% compared to control groups.

Brand names: Protivity
Other names: Mycoplasma Bovis Vaccine, Modified Live Culture

Targets

M. bovis (Mycoplasma bovis)

Beyond the preview

Go deeper on Protivity.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protivity.

Explore the full profile